Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Huangqi Yishen Capsule is a Traditional Chinese Medicine (TCM) product developed and manufactured by Lei Yun Shang. It is formulated as an oral capsule primarily indicated for the treatment of chronic glomerulonephritis and chronic kidney disease (CKD), particularly cases characterized by spleen and kidney Qi deficiency according to TCM principles. The primary active component is *Astragalus membranaceus* (Huangqi), which is traditionally used to tonify Qi and has been studied for its potential to reduce proteinuria, provide immunomodulatory effects, and protect renal function. As a TCM formulation, its therapeutic effect is attributed to the synergistic action of multiple herbal components rather than a single molecular target.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Huangqi Yishen Capsule.